Management of Head Injury in the CCU: Modalities to Reduce ICP

The Monroe-Kellie Doctrine (Physiological Basis)

Initial CCU Priorities (Before Specific ICP Reduction)

Monitoring

• ICP monitoring is indicated for GCS 3-8 with CT abnormalities, or GCS 3-8 with normal CT plus any two of: age >40, posturing, or systolic BP < 90 mmHg
• EVD (external ventricular drain) is the gold standard - gives both ICP readings and therapeutic CSF drainage
• Intraparenchymal bolt - easier to insert but cannot drain CSF
• CPP monitoring - continuous MAP - ICP calculation guides vasopressor and osmotic therapy

Avoid Secondary Insults

• Hypoxia (SpO2 < 95% is harmful; target PaO2 > 80 mmHg)
• Hypotension (SBP < 90 mmHg doubles mortality; target MAP > 80 mmHg)
• Hypercarbia (CO2 is a potent cerebral vasodilator - target PaCO2 35-45 mmHg)
• Hyperthermia (each 1°C rise increases cerebral metabolic rate ~7%; target normothermia)
• Hyponatremia (worsens cerebral edema)
• Hypoglycemia and severe hyperglycemia (both worsen neuronal injury)
• Fluid overload with hypotonic solutions (5% dextrose, 0.45% saline, lactated Ringer's are avoided; normal saline is preferred)

Tiered ICP Management (ACS TQIP / SIBICC Three-Tier Algorithm)

TIER 1 - First-Line Measures

TIER 2 - Escalation if ICP Persistently > 22 mmHg

1. Hyperosmolar Therapy

• Dose: 0.25 to 1.0 g/kg IV every 3-6 hours
• Mechanism: osmotic diuresis + initial rheological effect (reduces blood viscosity)
• Monitor serum osmolality q6h; hold if osmolality > 320 mOsm/L
• Preferred when: patient is hypervolemic/fluid overloaded (it is a potent diuretic)
• Caution: can cause renal failure (usually with >200 g/day), hypovolemia, rebound ICP

• 3% NaCl: boluses of 150 mL or continuous infusion 30-50 mL/hr
• 7.5% NaCl: 75 mL boluses
• 23.4% NaCl: 30 mL bolus (most potent, central line mandatory)
• Monitor serum Na q6h; hold if Na > 155-160 mEq/L
• Preferred when: patient is hypovolemic, already on mannitol, or has cardiac dysfunction (expands intravascular volume)
• Advantage over mannitol: avoids dehydration, does not cause rebound hypovolemia
• Recent meta-analyses (Bernhardt et al., Neurocrit Care 2024, PMID 37380894; Cai & He, Brain Inj 2024, PMID 38853675) confirm HTS is at least as effective as mannitol in lowering ICP in TBI; neither has shown a clear survival advantage over the other

2. Controlled Hyperventilation

• Hypocarbia causes cerebral vasoconstriction → reduces CBV → lowers ICP
• Target: PaCO2 30-35 mmHg (not below 30)
• Onset within minutes, but effect lasts only 20-40 minutes as CSF pH equilibrates
• Use only as a bridge (e.g., impending herniation) while preparing definitive treatment
• Avoid prophylactic hyperventilation - reduces cerebral perfusion and can cause ischemia
• Exception: imminent herniation (Cushing's triad, fixed dilated pupil) - hyperventilate as bridge to surgery

3. Neuromuscular Blockade (NMB)

• Assess with a single test dose of vecuronium or cisatracurium
• If ICP drops, start continuous infusion (Tier 3)
• Eliminates raised intrathoracic pressure from bucking, shivering, or ventilator dyssynchrony
• Requires continuous EEG because it masks clinical seizure activity

TIER 3 - Refractory Intracranial Hypertension

1. Barbiturate Coma

• Pentobarbital: loading dose 10 mg/kg over 30 min, then continuous infusion 1-4 mg/kg/hr
• Mechanism: profound reduction of CMRO2, CBF, and CBV
• Titrate to EEG burst suppression (continuous EEG monitoring mandatory)
• Side effects: hypotension (frequently requires vasopressors to maintain CPP), immunosuppression, ileus, prolonged sedation
• Consideration of barbiturate coma should simultaneously trigger consideration of decompressive craniectomy

2. Decompressive Craniectomy

• Surgical removal of a bone flap to allow brain expansion without rising ICP
• Indications: refractory ICP > 25 mmHg unresponsive to all medical measures
• Two landmark RCTs: DECRA and RESCUEicp - used persistently raised ICP as the trigger; craniectomy reduces ICP and mortality but survivors may have increased rates of severe disability
• Decision requires careful consideration of individual goals of care

3. Continuous Neuromuscular Blockade

• If Tier 2 NMB test dose was effective, proceed to continuous infusion
• Eliminates all movement-related ICP spikes

4. Therapeutic Hypothermia

• Reduces CMRO2 and ICP; target 35-36°C (modest) or 32-34°C (deep)
• Current evidence does not support routine prophylactic hypothermia in TBI
• Rewarming must be gradual to prevent rebound ICP

Surgical Modalities

Additional Supportive Measures

• Corticosteroids: contraindicated in TBI (CRASH trial showed increased mortality with methylprednisolone)
• Steroids are appropriate only for vasogenic edema from tumors, not traumatic edema
• Diuretics (furosemide): may augment effect of mannitol; used if cardiac volume overload limits HTS use
• Tranexamic acid (TXA): early administration (within 3 hours) in TBI patients with intracranial hemorrhage; reduces hemorrhage expansion
• Coagulopathy reversal: prothrombin complex concentrate (PCC) for anticoagulant reversal; desmopressin for antiplatelet agents
• Positioning: avoid tight cervical collars obstructing jugular venous drainage
• Avoid coughing/straining/Valsalva: ensure adequate sedation during suctioning

Quick Summary Table

• Adams and Victor's Principles of Neurology, 12th Ed., pp. 913-914
• Sabiston Textbook of Surgery (Biological Basis of Modern Surgical Practice), pp. 804-805
• Rosen's Emergency Medicine: Concepts and Clinical Practice, p. 70
• Bernhardt K et al. Hypertonic Saline Versus Other ICP-Lowering Agents for TBI - Neurocrit Care 2024 [PMID 37380894]
• Cai L & He W. Effectiveness of hypertonic saline infusion in TBI - Brain Inj 2024 [PMID 38853675]